Skip to main content

Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy.

Publication ,  Journal Article
Carrasquilla, M; Creswell, ML; Pepin, AN; Wang, E; Forsthoefel, M; McGunigal, M; Bullock, E; Lei, S; Collins, BT; Lischalk, JW; Esposito, G ...
Published in: Front Oncol
2020

Lymph node recurrent prostate cancer is a common clinical scenario that is likely to increase significantly with the widespread adoption of novel positron emission tomography (PET) agents. Despite increasing evidence that localized therapy is disease modifying, most men with lymph node recurrent prostate cancer receive only systemic therapy with androgen deprivation therapy (ADT). For men who receive localized therapy the intent is often to delay receipt of systemic therapy. Little evidence exists on the optimal combination of local and systemic therapy in this patient population. In this hypothesis generating review, we will outline the rationale and propose a framework for combining involved field SBRT with risk adapted intermittent ADT for hormone sensitive nodal recurrent prostate cancer. In patients with a limited number of nodal metastases, involved field stereotactic body radiation therapy (SBRT) may have a role in eliminating castrate-resistant clones and possibly prolonging the response to intermittent ADT. We hypothesize that in a small percentage of patients, such a treatment approach may lead to long term remission or cure.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Front Oncol

DOI

ISSN

2234-943X

Publication Date

2020

Volume

10

Start / End Page

606260

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Carrasquilla, M., Creswell, M. L., Pepin, A. N., Wang, E., Forsthoefel, M., McGunigal, M., … Collins, S. P. (2020). Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy. Front Oncol, 10, 606260. https://doi.org/10.3389/fonc.2020.606260
Carrasquilla, Michael, Michael L. Creswell, Abigail N. Pepin, Edina Wang, Matthew Forsthoefel, Mary McGunigal, Elizabeth Bullock, et al. “Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy.Front Oncol 10 (2020): 606260. https://doi.org/10.3389/fonc.2020.606260.
Carrasquilla M, Creswell ML, Pepin AN, Wang E, Forsthoefel M, McGunigal M, Bullock E, Lei S, Collins BT, Lischalk JW, Esposito G, Aghdam N, Kumar D, Suy S, Leger P, Hankins RA, Dawson NA, Collins SP. Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy. Front Oncol. 2020;10:606260.

Published In

Front Oncol

DOI

ISSN

2234-943X

Publication Date

2020

Volume

10

Start / End Page

606260

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis